Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Despina Fotiou

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 25, 2022
Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosisGeorgia Trakada, Despina Fotiou, Anastasios Kallianos, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 20, 2023
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression OutcomesEfstathios Kastritis, Maria Gavriatopoulou, Eirini Solia, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|October 23, 2021
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective StudyEvangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, et al.
Hemasphere|January 25, 2020
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyKonstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Blood|February 26, 2025
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaEvangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, et al.
Ejhaem|August 19, 2024
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myelomaMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
Blood Cancer Journal|November 9, 2018
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT studyDespina Fotiou, Theodoros N Sergentanis, Loula Papageorgiou, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 25, 2022
Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosisGeorgia Trakada, Despina Fotiou, Anastasios Kallianos, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 20, 2023
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression OutcomesEfstathios Kastritis, Maria Gavriatopoulou, Eirini Solia, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|October 23, 2021
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective StudyEvangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, et al.
Hemasphere|January 25, 2020
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyKonstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Blood|February 26, 2025
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaEvangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, et al.
Ejhaem|August 19, 2024
ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myelomaMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
Blood Cancer Journal|November 9, 2018
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT studyDespina Fotiou, Theodoros N Sergentanis, Loula Papageorgiou, et al.
Pageof 11